Hyperion Therapeutics Gets $40M

South San Francisco-based Hyperion Therapeutics said today that it has added $40M in a Series B funding round. The firm said that the round came from Sofinnova Ventures, which led the round, along with Highland Capital Partners, NEA, and WRF Capital. Hyperion Therapeutics is developing biopharmaceuticals, focused on gastrointestinal and hepatology therapies for the treatment of Urea Cycle Disorders (UCD) and Hepatic Encephalopathy (HE). James Healy of Sofinnova, Mike Raab of NEA, Bijan Salehizadeh of Highland, and Don Santel, former CEO of CoTherix, have joined the firm's board in conjunction with the funding.